PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 19, 2026ESMO Open0 citationsOpen Access

317P A phase II clinical study of neoadjuvant immunogenic radiotherapy followed by ivonescimab (PD-1/VEGF-A bispecific antibody) and chemotherapy in stage II-III non-small cell lung cancer

View Full Paper
XLX. LvZLZ. LiuMSM. Shi

Key Points

  • Evaluate the efficacy and safety of neoadjuvant immunogenic radiotherapy with ivonescimab and chemotherapy in stage II-III NSCLC.
  • Phase II clinical study design
  • Combination of immunogenic radiotherapy, ivonescimab, and chemotherapy
  • Focus on patients with resectable stage II-III NSCLC
  • Improved pathological response associated with combination therapy
  • Potential correlation between treatment and survival benefit observed

Abstract

In recent years, neoadjuvant immunotherapy combined with chemotherapy has been increasingly applied in resectable non-small cell lung cancer (NSCLC). An improved pathological response correlates with survival benefit. This study is to evaluate the efficacy and safety of combining immunomodulatory radiotherapy with ivonescimab and chemotherapy in stage II–III NSCLC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lv et al. (2026) studied this question.

synapsesocial.com/papers/69bb928c496e729e6297fe2bhttps://doi.org/10.1016/j.esmoop.2026.106627
Ask AI
Helpful
Bookmark
Share
View Full Paper